New Abortion Pill Reversal Study Published in Peer-Review Journal

April 5th 2018

Progesterone Protocol Offers Second Chance for Women Who Change Their Minds After Beginning the Medical Abortion Procedure

San Diego, California (April 4, 2018) - A new medical study looking at the use of progesterone to reverse mifepristone (RU-486) medical abortions is being published in the peer-reviewed medical journal, Issues in Law and Medicine. Women who change their minds after taking mifepristone, the first drug in the medical abortion process, now have a safe and effective way to reverse their medical abortions. 

Progesterone is the hormone essential to the maintenance of a normal, healthy pregnancy. Mifepristone is a progesterone receptor blocker. In the United States, 30 to 40% of all abortions are mifepristone medical abortions.

The study, looking at 261 successful mifepristone reversals, showed that the reversal success rates were 68% with the high-dose oral progesterone protocol and 64% with the injected progesterone protocol; both were significantly better rates than the 25% survival rate if no treatment is offered. There was no increased risk of birth defects or preterm births. Progesterone has been used safely in pregnancy for over 40 years. The authors included George Delgado, M.D. and Mary Davenport, M.D., who have been studying reversing the effects of mifepristone since 2009.

Link to article:

Dr. Delgado commented, “Women who change their minds after starting a medical abortion now have a second chance at choice. Using progesterone to reverse the effects of mifepristone is effective and does not increase the risks of birth defects.” 

One client wrote, “I just wanted to say, thank you from the bottom of my heart!!!” Another stated: “changed my entire world by helping me that night. This is the best feeling in the world and nothing else matters. Thank you.”

Women who decide to attempt the reversal of the medical abortion process now have new hope. Mifepristone reversal using progesterone is safe and effective. For more information, please visit

About the Authors of the Study: Dr. Delgado is the medical director of Culture of Life Family Services in San Diego, CA. Dr. Davenport is the Medical Director of Magnificat Maternal Health; she is based in El Sobrante, CA.

Click here to schedule Dr. Delgado for a speaking engagement.



For interviews or more information, please contact:

Sara Littlefield
Culture of Life Family Services


< Back